LQDA

Liquidia Corporation

Healthcare
Medical - Pharmaceuticals
$5.94B market cap

Forecast run · Sep 14, 2026Upside rank 317 of 3,136

Model Signal

ForecastQ Daily Probabilities

61.5%

37.0%

31.7%

Analyst Consensus

Recommendation2.14/5 Buy

Last price$66.74

Price target$98.11

Implied move+47.0%

Analysts7

ForecastQ Portfolios

LQDA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.